Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
41.68 ^USD	+0.65%		-2.98%	-30.73%

May. 24	HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating	MT
May. 24	Deutsche Bank Starts Legend Biotech With Buy Rating	MT

Legend Biotech Announces Executive Changes

April 03, 2022 at 06:26 am EDT

Legend Biotech Corporation announced the appointment of Guowei Fang, Ph.D., as senior vice president, global head of research and early development of Legend Biotech. Dr. Guowei Fang will assume the responsibilities of Dr. Xiaohu Fan, who resigned from Legend Biotech effective on 30 March 2022. Dr. Guowei Fang is an accomplished scientist and pharmaceutical research and development leader who brings a wealth of experience in oncology and immunology to the role.

Dr. Fang comes to Legend Biotech from Zymeworks Inc, where he served as senior vice president of Research and oversaw the development of novel platforms and a portfolio of multi-functional biologics and antibody drug conjugates.

Latest news about Legend Biotech Corporation

HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating	May. 24	MT
Deutsche Bank Starts Legend Biotech With Buy Rating	May. 24	MT
Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA	May. 23	CI
MaxCyte inks deal with Legend Biotech for tech supply	May. 22	AN
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	May. 22	MT
Legend Expects to Log Profit in 2026	May. 15	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating	May. 14	MT
Legend Biotech's Loss Narrows in Q1 as Revenue Surges	May. 14	MT
RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating	May. 14	MT
Sector Update: Health Care Stocks Decline Pre-Bell Monday	May. 13	MT
Sector Update: Health Care	May. 13	MT
Transcript : Legend Biotech Corporation, Q1 2024 Earnings Call, May 13, 2024	May. 13
Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell	May. 13	MT
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales	May. 13	DJ
Stock Futures Rise Pre-Bell Ahead of Key Inflation Data; Asia, Europe Churn	May. 13	MT
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q1 Revenue $94M	May. 13	MT
Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	Apr. 23	MT
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	Apr. 22	MT
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	Apr. 22	CI
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	Apr. 17	MT
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	Apr. 17	MT
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	Apr. 08	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT

Chart Legend Biotech Corporation

Duration

Period

More charts

Company Profile

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Sector

Biotechnology & Medical Research

Calendar

2024-06-03 - American Society of Clinical Oncology Meeting - Abstract Number: #7535

More about the company

Income Statement Evolution

More financial data

Ratings for Legend Biotech Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.68 USD

Average target price

83.03 USD

Spread / Average Target

+99.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LEGEND BIOTECH CORPORATION	-30.73%	7.6B
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.83%	21.83B
GENMAB A/S	-10.86%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs